<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908841</url>
  </required_header>
  <id_info>
    <org_study_id>16-02-37-337</org_study_id>
    <nct_id>NCT02908841</nct_id>
  </id_info>
  <brief_title>Surgicel Snow in Gynecological Surgery</brief_title>
  <official_title>Surgicel Snow in Gynecological Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danbury Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwalk Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danbury Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgicel Snow is an FDA approved topical hemostatic agent for use during surgical procedures.
      Like the other mechanical agents, Surgicel Snow forms a physical barrier that blocks blood
      flow while providing a large surface area for the rapid formation of a fibrin clot. As a
      mechanical agent derived from oxidized regenerated cellulose, Surgicel Snow shares with other
      mechanical hemostatic agents, the benefits of a favorable risk profile. This study would
      examine the efficacy of Surgicel Snow vs. direct compression in the control of capillary,
      venous, and small arterial hemorrhage when ligation or other conventional methods of control
      are impractical or ineffective in patients undergoing laparoscopic or robotic assisted
      laparoscopic hysterectomy. The intraoperative inclusion bleeding characteristics are minimal
      and mild retroperitoneal bleeding and moderate retroperitoneal bleeding that has been
      adequately reduced by standard surgical methods. 60 patients will be recruited for this
      study, all of which will be scheduled for hysterectomy at Western Connecticut Health Network
      (Norwalk Hospital and Danbury Hospital) under the direction of Dr. Thomas Rutherford, Dr.
      John Garofalo, and Dr. Robert Samuelson. The investigators will randomize 30 patients to the
      treatment group and 30 patients to the control group. Participants may continue all regular
      medications before and during the study. The consent process will be incorporated into the
      last pre-operative office visit. The health risks associated with use of Surgicel Snow may be
      less, the same or more than direct pressure alone. Surgicel Snow is generally used for
      minimal to mild bleeding from specific or widespread area; however, its effectiveness
      compared to direct pressure is unknown for a hysterectomy surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bleeding at specified time intervals</measure>
    <time_frame>4 minutes, 7 minutes and 10 minutes</time_frame>
    <description>Because multiple factors other than retroperitoneal bleeding contribute to the total intraoperative bleed loss, the investigators believe that the intraoperative estimated blood loss is not a pure indicator of the efficacy of a topical hemostatic agent for control of retroperitoneal bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Operative Time</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative Blood Loss</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hemoglobin decrease</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative symptomatic fluid collection</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pelvic abscess</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cost of care determined through retrospective review of billing records</measure>
    <time_frame>Through study completion, an average of 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Laparoscopic Hysterectomy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 patients randomized to the control group and will receive standard of care. Control patients will be managed with direct compression with gauze pads or laparotomy pads for four minutes. If hemostasis is not achieved by compression after four minutes, the source and rate of bleeding will be reevaluated and management will be determined by the surgeon. If the surgeon uses SurgicelSnow to achieve hemostasis at some point after 4 minutes, the patient will be included in the control group, but the data will be and flagged for the analysis. If failure of hemostasis at 4 minutes with an estimated loss of ≥25 cc/min, patient will be managed as per judgment of surgeon. Persistent bleeding at the 10 minute observation point will be treated as per the surgeon's judgment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 patients randomized to the treatment group will receive Surgicel Snow. For patients with qualifying bleeding (rated on initial evaluation as at least &quot;mild&quot;) who have been randomized to receive Surgicel Snow, a single thin layer of dry Surgicel Snow will be applied over the area of bleeding and positioned firmly in direct contact to the areas of bleeding with blunt surgical instruments. Surgicel Snow will be left in the cavity to be absorbed. Dry gauze will not be placed over the material. No adjuncts will be added to the enhance hemostasis, but patients with small arteriolar bleeding will have pressure maintained on the bleeding site for 60 seconds. Hemostatic failure at 4 minutes will be reassessed for rate of blood loss and if the rate of loss is estimated at less than 25 cc per minute, additional observations will be made at 7 and 10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgicel Snow</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Women ≥18 years of age

          2. Women scheduled for standard multiport laparoscopic, single site laparoscopic, and
             robotic assisted laparoscopic hysterectomy.

          3. Sites of surgery include Norwalk Hospital and Danbury Hospital.

          4. Indication for surgery includes benign, complex benign, and malignant conditions.

          5. Signed informed consent

        Exclusion criteria:

          1. Vaginal hysterectomy or open abdominal hysterectomy;

          2. Congenital or acquired coagulation disorder including recent (within 7 days of
             surgery) therapeutic anticoagulation or use agents affecting platelet function, other
             than low dose aspirin. (Preoperative prophylactic heparin is not an exclusion
             criterion.)

          3. Hysterectomy at the time of sacrocolpopexy.

          4. Ovarian cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Garofalo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physicians for Women's Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren DiLello</last_name>
    <phone>2037396340</phone>
    <email>lauren.dilello@wchn.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siobhan Flynn</last_name>
      <phone>203-739-7754</phone>
      <email>siobhan.flynn@wchn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Physicians for Women's Health</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren DiLello</last_name>
      <phone>203-739-6340</phone>
      <email>lauren.dilello@wchn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren DiLello</last_name>
      <phone>203-739-6340</phone>
      <email>lauren.dilello@wchn.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://journals.lww.com/jpelvicsurgery/Fulltext/2003/05000/Anatomy_of_the_Pelvis.1.aspx</url>
  </link>
  <link>
    <url>http://journals.lww.com/greenjournal/Fulltext/2013/03000/Complications_of_Hysterectomy.23.aspx</url>
  </link>
  <link>
    <url>http://dx.doi.org/10.1007/s10570-012-9828-8</url>
  </link>
  <reference>
    <citation>Spangler D, Rothenburger S, Nguyen K, Jampani H, Weiss S, Bhende S. In vitro antimicrobial activity of oxidized regenerated cellulose against antibiotic-resistant microorganisms. Surg Infect (Larchmt). 2003 Fall;4(3):255-62.</citation>
    <PMID>14588160</PMID>
  </reference>
  <reference>
    <citation>Martyn D, Kocharian R, Lim S, Meckley LM, Miyasato G, Prifti K, Rao Y, Riebman JB, Scaife JG, Soneji Y, Corral M. Reduction in hospital costs and resource consumption associated with the use of advanced topical hemostats during inpatient procedures. J Med Econ. 2015 Jun;18(6):474-81. doi: 10.3111/13696998.2015.1017503. Epub 2015 Mar 26.</citation>
    <PMID>25728820</PMID>
  </reference>
  <reference>
    <citation>Ata B, Turkgeldi E, Seyhan A, Urman B. Effect of hemostatic method on ovarian reserve following laparoscopic endometrioma excision; comparison of suture, hemostatic sealant, and bipolar dessication. A systematic review and meta-analysis. J Minim Invasive Gynecol. 2015 Mar-Apr;22(3):363-72. doi: 10.1016/j.jmig.2014.12.168. Epub 2015 Jan 5. Review.</citation>
    <PMID>25573183</PMID>
  </reference>
  <reference>
    <citation>Santulli P, Marcellin L, Touboul C, Ballester M, Darai E, Rouzier R. Experience with TachoSil in obstetric and gynecologic surgery. Int J Gynaecol Obstet. 2011 May;113(2):112-5. doi: 10.1016/j.ijgo.2010.11.019. Epub 2011 Mar 30.</citation>
    <PMID>21453918</PMID>
  </reference>
  <reference>
    <citation>Angioli R, Muzii L, Montera R, Damiani P, Bellati F, Plotti F, Zullo MA, Oronzi I, Terranova C, Panici PB. Feasibility of the use of novel matrix hemostatic sealant (FloSeal) to achieve hemostasis during laparoscopic excision of endometrioma. J Minim Invasive Gynecol. 2009 Mar-Apr;16(2):153-6. doi: 10.1016/j.jmig.2008.11.007. Epub 2009 Jan 9.</citation>
    <PMID>19138574</PMID>
  </reference>
  <reference>
    <citation>Ribeiro SC, Reich H, Rosenberg J, Guglielminetti E, Vidali A. Laparoscopic myomectomy and pregnancy outcome in infertile patients. Fertil Steril. 1999 Mar;71(3):571-4.</citation>
    <PMID>10065802</PMID>
  </reference>
  <reference>
    <citation>Raga F, Sanz-Cortes M, Bonilla F, Casañ EM, Bonilla-Musoles F. Reducing blood loss at myomectomy with use of a gelatin-thrombin matrix hemostatic sealant. Fertil Steril. 2009 Jul;92(1):356-60. doi: 10.1016/j.fertnstert.2008.04.038. Epub 2009 May 6.</citation>
    <PMID>19423098</PMID>
  </reference>
  <reference>
    <citation>Angioli R, Plotti F, Ricciardi R, Terranova C, Zullo MA, Damiani P, Montera R, Guzzo F, Scaletta G, Muzii L. The use of novel hemostatic sealant (Tisseel) in laparoscopic myomectomy: a case-control study. Surg Endosc. 2012 Jul;26(7):2046-53. doi: 10.1007/s00464-012-2154-2. Epub 2012 Feb 1.</citation>
    <PMID>22302534</PMID>
  </reference>
  <reference>
    <citation>Shander A, Kaplan LJ, Harris MT, Gross I, Nagarsheth NP, Nemeth J, Ozawa S, Riley JB, Ashton M, Ferraris VA. Topical hemostatic therapy in surgery: bridging the knowledge and practice gap. J Am Coll Surg. 2014 Sep;219(3):570-9.e4. doi: 10.1016/j.jamcollsurg.2014.03.061. Epub 2014 Jun 2. Review.</citation>
    <PMID>25151345</PMID>
  </reference>
  <reference>
    <citation>Wysham WZ, Roque DR, Soper JT. Use of topical hemostatic agents in gynecologic surgery. Obstet Gynecol Surv. 2014 Sep;69(9):557-63. doi: 10.1097/OGX.0000000000000106.</citation>
    <PMID>25229825</PMID>
  </reference>
  <reference>
    <citation>Parker WH, Wagner WH. Gynecologic surgery and the management of hemorrhage. Obstet Gynecol Clin North Am. 2010 Sep;37(3):427-36. doi: 10.1016/j.ogc.2010.05.003. Review.</citation>
    <PMID>20674784</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

